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Abstract- High reliability water quality guideline values (GVs) have been derived for four 28 
pharmaceuticals, carbamazepine, diclofenac, fluoxetine and propanolol in fresh waters using 29 
a Burr Type III distribution applied to species sensitivity distributions (SSDs) of chronic 30 
toxicity data. Data were quality assured and had to meet acceptability criteria for ‘chronic’ 31 
NOEC or EC10 endpoints including population relevance (namely, effect endpoints based on 32 
development, growth, reproduction and survival). Biomarker response data (e.g. biochemical, 33 
histological or molecular responses) were excluded from the derivation as they are typically 34 
not directly relevant to population-related impacts. The derived GVs for 95% species 35 
protection were 4.3, 770, 1.6 and 14 µg/L for carbamazepine, diclofenac, fluoxetine and 36 
propranolol, respectively. These values significantly higher than the low reliability values 37 
derived for the European Commission, Switzerland or Germany that are based on the 38 
application of assessment factors to the most sensitive experimental endpoint (which may 39 
include biochemical, histological or molecular biomarker responses). The GVs derived in this 40 
exercise were not exceeded in recent data for Australian rivers and streams receiving 41 
pharmaceutical containing effluents from WWTPs.   42 
Keywords 43 
Pharmaceutical, carbamazepine, diclofenac, fluoxetine, propanolol 44 
 45 
  46 
5  
 47 
INTRODUCTION 48 
 49 
Our growing dependence on pharmaceuticals, and their increased availability to 50 
consumers, means that a number of the commonly used products are becoming detectable 51 
constituents of wastewaters [1, 2]. Depending on the effectiveness of the wastewater 52 
treatment process, there are real prospects for these products to reach natural water systems, 53 
with the potential for effects on aquatic ecosystem health. Ecotoxicological investigations 54 
have been carried out for many of the popularly used pharmaceuticals, however, there have 55 
been limited attempts to derive water quality guidelines that enable regulatory agencies to 56 
determine whether measured environmental concentrations pose a concern.    57 
This paper collates the available data for four pharmaceuticals, carbamazepine, 58 
diclofenac, fluoxetine and propranolol, and derives high reliability guideline values for 59 
ecosystem protection of 99, 95 and 90% of species using species sensitivity distributions 60 
(SSDs) [3]. The latest revisions to the guideline derivation protocols [4] were applied. These 61 
involve: 62 
(i) Using effects endpoints for development, growth, reproduction or survival and 63 
focussing on chronic EC10 data, where available, rather than NOEC data and excluding 64 
biomarker responses (e.g. biochemical, histological or molecular responses); 65 
(ii) Ensuring that all toxicity data meet the required definitions of chronic tests, in 66 
particular, for juvenile fish tests, exposure duration should be ≥21 days and ≥7 days for 67 
fish embryo tests; 68 
(iii)  High reliability guideline values require 8 or more data points for chronic exposure (no 69 
conversions of acute data to chronic) representing at least 4 taxonomic groups; 70 
(iv)  The goodness of fit of data to the Burr Type III distribution used in the SSD being 71 
acceptable; and 72 
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(v) Careful evaluation of all data to ensure they meet acceptability criteria (Batley et al., 73 
2013).  74 
The basic data for each of the pharmaceuticals are summarised in Table 1. 75 
 76 
EXPERIMENTAL 77 
A thorough review of the literature was undertaken for all toxicity data relating to 78 
carbamazepine, diclofenac, fluoxetine and propanolol and added to a new dataset determined 79 
in our laboratories [5]. Since our priority is ecological protection based on population-80 
relevant endpoints, adverse effects on development, growth, reproduction and survival were 81 
used to derive NOEC or EC10 values, as per the recommendation by Hutchinson et al. [6]. 82 
This approach recognizes that biomarkers responses based on biochemical, histological and 83 
molecular endpoints may be highly useful for exposure monitoring [7, 8] and also in 84 
developing adverse outcome pathways to help prioritize appropriate testing strategies for 85 
ecotoxicology research and risk assessment [9]. Data were sorted into acute and chronic tests, 86 
with the objective of obtaining at least 8 chronic NOEC or EC10 data points for species from 87 
4 or more taxonomic groups. If this was achieved, acute data and chronic data having other 88 
endpoints (e.g. EC50 or LOECs) were discarded, otherwise lower reliability guidelines could 89 
be generated using a combination of converted acute data (using an ACR or default value of 90 
10) and chronic data. A quality check of the data as described by Hobbs et al. [10] was then 91 
undertaken and only data of high or acceptable quality were retained as recommended for 92 
guideline derivation in Australia and New Zealand [4]. 93 
Data were then screened to ensure that the endpoints reported were acceptable as 94 
chronic tests according to agreed criteria [4, 10]. An SSD was then obtained from the data set 95 
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using the BurrliOz Version 2 software to derive guideline values (GVs) that were protective 96 
of 99, 95 and 90% of species (PC99, PC95 and PC90) with 50% confidence.  97 
 98 
RESULTS AND DISCUSSION 99 
Carbamazepine 100 
A review of the literature found acute toxicity data reported for 6 species, and chronic 101 
toxicity for 17 species. Of these, acceptable chronic toxicity data were available for 11 102 
species (2 cladocerans, 2 green algae, 1 blue-green algae, 1 diatom, 1 midge, 1 rotifer, 1 103 
cnidarian and 2 fish) representing 8 taxonomic groups (Table 2). The cladoceran, 104 
Ceriodaphnia dubia, was the most sensitive, with an EC10 of 25 µg/L [11].  The data 105 
distribution using a Burr Type III fit in the SSD was such that it had a long tail (Figure 1), 106 
which meant that a 99% protection GV could not be determined. The 95% protection GV was 107 
4.3 µg/L (Table 6).   108 
Carbamazepine enters the environment largely through discharges from wastewater 109 
treatment plants, in which it is not effectively removed [12, 13].
  
It has been detected in 110 
discharges from German plants at concentrations up to 6.3 µg/L [14]. Loos et al. [15] 111 
reported a mean concentration of 250 ng/L (maximum 12 µg/L) in studies of 122 European 112 
river waters.   Indian rivers contained 6-128 ng/L [16] while in Spanish rivers 80-3090 ng/L 113 
[17] and in the Pearl River in China, 43 ng/L [18]. It has a relative long half-life of 38 days in 114 
natural waters in the presence of sunlight, with photolysis being the major degradation 115 
pathway [12]. Tixier et al. [19] reported a half-life of 63 days in Lake Greifensee in 116 
Germany, indicating that it was relatively persistent. 117 
In all cases, detected concentrations in receiving waters were below the derived GV.  118 
The guidelines recommended in Switzerland and Germany [20, 21] are considerably lower 119 
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(Table 7). The Swiss environmental quality standard (EQS) of 0.5 µg/L was derived by 120 
applying an assessment factor of 50 to the most sensitive reliable endpoint, that for 121 
reproduction of Ceriodaphnia dubia (25 µg/L) [22]. The available fish data were only for a 122 
10-d exposure and considered not acceptable for a chronic test, although in Australia and 123 
New Zealand, the 7-d test is acceptable for fish embryos and a 21-d test required for juvenile 124 
fish [4]. In the Swiss study, the scope of the data analysis included both adverse effects data 125 
and biomarker responses in contrast to our focus solely on population-relevant effects [22]. 126 
Their GV is clearly of low reliability compared to that derived in this paper.  Ferrari et al. 127 
[23] using a limited dataset and a log-normal distribution in a SSD, determined 95% 128 
protection value (reported as a hazardous concentration to 5% of species, HC5) of 2.1 µg/L. 129 
(Table 7), comparable to our value of 4.3 µg/L with a large dataset.  130 
 131 
Diclofenac 132 
Of 13 chronic data for diclofenac, 11 had EC10 or NOEC values suitable for GV 133 
derivation.  These comprised 2 cladocerans, 1 diatom, 2 green algae, 1 blue-green algae, 1 134 
rotifer, 1 angiosperm, 1 arthropod and 2 fish, representing 8 taxonomic groups.  The most 135 
sensitive species was the midge, Chironomus tepperi with an EC10 of 760 µg/L [5]. 136 
 137 
Schmitt-Jansen et al. [24] exposed the green alga Scenedesmus vacuolatus to 138 
diclofenac in ultrapure water to sunlight and noted an increase in toxicity measured as growth 139 
inhibition, with time over 6 days, with the EC50 decreasing from 46.3 mg/L to 23 µg/L after 140 
6 days. There was a rapid decrease in diclofenac concentrations due to photodegradation and 141 
the enhanced toxicity was clearly due to the presence of degradation products. These data 142 
were not included as the tests were not conducted in natural waters and the pH was not 143 
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recorded, nor EC10 values calculated. It is unclear how the results relate to actual field 144 
conditions.  145 
Concentrations in the range 310-930 ng/L have been detected in the effluents from a 146 
Swiss wastewater treatment plant, with concentrations only marginally reduced during 147 
passage through the plant [25]. Diclofenac has been detected at <1-12 ng/L in Swiss lakes 148 
and 11-310 ng/L in a nearby river [25] and from 110-220 ng/L in the Höje River in Sweden 149 
downstream of a WWTP [26]. Photolysis is the major degradation pathway with half-lives 150 
near 3 h at summer temperatures [24] (Buser et al. [25] reported 0.9 h), but up to 2 days in 151 
winter in some locations [27]. Diclofenac is ionised at the pH of most waters (pKa=4.2), so is 152 
not readily volatilised, nor does it readily attach to particulates [25].  153 
The measured concentrations are below the GV derived in this study (Table 6), but 154 
would exceed the proposed EQS for the European Commission (reported in Europe (Johnson 155 
et al., 2013) (Table 7). A discussion paper on the EU guidelines [28] indicated that these 156 
values are derived by applying an assessment factor of 10 to the lowest acceptable NOEC, for 157 
a fish.  For rainbow trout, both Schwaiger et al. [29] and Triebskorn [30] reported a LOEC of 158 
1 µg/L for a histopathological effect, while the latter referred to a threshold of 5 µg/L for 159 
histopathological lesions.  A NOEC of 0.5 µg/L was reported by Hoeger et al. [31] for 160 
monocyte infiltration/accumulation in livers of brown trout exposed to diclofenac for 21 161 
days. They concluded that the adverse effects in various organs could ‘possibly compromise 162 
fish health’. The EQS of 0.05 µg/L proposed by the Swiss Ecotox Centre [32] was based on 163 
the application of an assessment factor of 10 to the above NOEC for brown trout.   164 
The current Australian and New Zealand approach to biomarker endpoints of this type 165 
is that they should not be used in the derivation of water quality guidelines, unless their 166 
ecological relevance can be demonstrated [4]. This approach is consistent with that of 167 
Hutchinson et al. [33] who advocated that biomarker responses or signals (such as 168 
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vitellogenin, secondary sexual characteristics, gonadosomatic index, gonad histology, plasma 169 
steroids, enzyme induction and gene expression) may provide valuable mechanistic signals to 170 
guide chronic testing for adverse effects and, at present, should not be used to directly derive 171 
water quality guidelines. Moreover, it is recognized that interpretation of many biomarkers 172 
responses in aquatic organisms is highly complex [33-35]. Acceptable population-relevant 173 
effects endpoints include survival, length, weight, development, fecundity, fertilisation rate, 174 
hatching success and sex ratios. The focus on population-relevant endpoints for setting GVs 175 
for pharmaceuticals is also proposed by Caldwell et al. [36, 37]. 176 
The use of an assessment factor results in a conservative, very low reliability GV.  By 177 
contrast, the GV derived in this study would be classified as high reliability based on the 178 
criteria being adopted for Australian and New Zealand water quality guideline derivation [4]. 179 
Using a limited data set, Ferrari et al. [23] applied a log normal distribution in an SSD to 180 
derive an HC5 that protected 95% of species that was of the same order of magnitude as our 181 
value of 770 µg/L. 182 
SCHER [28] raised a concern regarding the solubility of diclofenac being exceeded in 183 
some of the toxicity tests, however, data from Llinas et al. [38] suggest that this would only 184 
be an issue in mildly acidic solutions below the diclofenac pKa. At the pH of natural waters, 185 
solubility limitations would not be an issue. 186 
  187 
Fluoxetine 188 
There is a large toxicity database for fluoxetine, comprising both acute and chronic 189 
tests as well as others based on behavioural and biomarker endpoints. Of these only 13 190 
reported chronic NOEC or EC/IC10 endpoints, comprising 6 green algae, 1 arthropod, 1 191 
angiosperm, 3 crustaceans, 1 gastropod and 1 fish, representing 6 taxonomic groups (Table 192 
4). Oakes et al. [39] found that the green alga Desmodesmus subspicatus was the most 193 
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sensitive species to fluoxetine with a NOEC was ≤0.6 µg/L. Given that NOECs are not a 194 
reliable endpoint, most jurisdictions, including Australia and New Zealand, recommend the 195 
use of EC/IC10 values as a more defensible alternative [4]. In the supplementary information 196 
to Oakes et al. [39], the plotted dose response curve showed an IC10 of 1 µg/L and so this 197 
was included in the database used in this study. Along with this species, the New Zealand 198 
mud snail, Potamopygus antipodarum was also very sensitive (Table 4) [40, 41].
  
199 
The malformation endpoint for the African clawed frog, Xenopus laevis [42] (Table 4) 200 
was deemed unacceptable for use in GV derivation as many non-contaminant factors can lead 201 
to malformations The 7-d juvenile fish data for fathead minnow [43] were considered acute 202 
and not chronic according to the Australian and New Zealand data selection criteria [4] which 203 
require a 21-d test, so this too was not included. 204 
 205 
Fluoxetine is a racemate, a mixture of two sterioisomers with mirror-image structures 206 
[4]. The (R)-enantiomer is known as dextro-propranolol. The (S)-enantiomer is known as 207 
levo-fluoxetine.  The most common form is as a racemic mixture (1:1) of the sterioisomers, 208 
supplied as the hydrochloride. To date only one study has examined the chronic toxicity of 209 
the sterioisomers and found that (S)-fluoxetine was more toxic than (R)-fluoxetine to fathead 210 
minnow, Pimephales promelas, while there was no significant difference in the responses of 211 
Daphnia magna [4]. Fluoxetine photodegradation has a relatively long half-life (160 days) 212 
[44] and its relatively high Kow means that it binds preferentially to particulate organic matter.   213 
Measured concentrations of fluoxetine in natural waters are typically in the ng/L 214 
range.  Kolpin et al. [45] reported a median concentration of 12 ng/L for a range of US 215 
streams, and similar values have been reported for waters in Canada and the UK [39]. WWTP 216 
effluent concentrations are typically <500 ng/L [46-48]. 217 
12  
The high reliability GV for fluoxetine derived in this study was 1.6 µg/L for 95% 218 
species protection.  No reported EQS values could be found, however, a number of studies 219 
reported predicted no effects concentrations (PNECs) for fluoxetine in surface waters. These 220 
were all obtained by applying assessment factors to the most sensitive data (Table 7). Thus 221 
Oakes et al. [39] obtained a PNEC of 0.012 µg/L by applying a factor of 50 to the D. 222 
subspicatus data.  Montforts [49] reported a PNEC of 0.031 µg/L using a factor of 1000 with 223 
algal toxicity data.  Grung et al. [50] reported a PNEC of 0.004 µg/L, while Verlicchi et al. 224 
[2] reported a PNEC of 0.05 µg/L. All of these values are conservative and of very low 225 
reliability.  226 
Sumpter et al. [51] have discussed the fact that both vertebrates and invertebrates use 227 
serotonin as a neurotransmitter and, as such, fluoxetine as a serotonin reuptake inhibitor, may 228 
have effects on fish (and invertebrate) behaviour (e.g. swimming speed, schooling 229 
behaviour).  Such non-standard endpoints have not been considered on our GV derivation.  230 
 231 
Propranolol 232 
Although there are published results for over 20 chronic toxicity tests, only 12 233 
reported chronic NOEC or EC10 values, with the remainder only giving EC50 or LOEC 234 
values. Although both an EC10 and an EC5 were available for the green algae, Desmodesmus 235 
subspicatus, because of the greater errors around the EC5, the EC10 value was used for 236 
guideline derivation [52]. 237 
Data were obtained for 2 cladocerans, 1 diatom, 2 green algae, 1 blue-green algae, 1 238 
rotifer, 1 angiosperm, 1 arthropod and 3 fish, representing 8 taxonomic groups.  Of these, the 239 
fathead minnow, Pimephales promelas [53] and the cladoceran, Ceriodaphnia dubia, were 240 
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the most sensitive [54].
 
 Like fuoxetine, propranolol is a racemate [55], with the most 241 
common form a racemic mixture (1:1) of the sterioisomers, supplied as the hydrochloride. 242 
Propranolol has been detected in WWTP effluents in Germany at a median 243 
concentration of 170 ng/L (290 ng/L maximum) [14] and in Sweden near 30 ng/L [26].  244 
Downstream river water concentrations were closer to 12 ng/L (590 ng/L maximum) and 10 245 
ng/L respectively. High concentrations are unlikely to persist as the laboratory-determined 246 
half-life for photolytic decomposition was 1.1 h [56]. For sunlight exposure, Liu et al. [57] 247 
extrapolating from laboratory studies calculated a half-life closer to 1 day in summer and 8 248 
days in winter, with photodegradation being up to 19 times faster than biodegradation.  249 
Our study yielded a high reliability guideline value for propranolol of 14 µg/L. This is 250 
almost 100-fold higher than the value recommended for Switzerland [32]. Their low 251 
reliability EQS of 0.16 µg/L (Ecotox Centre, 2013d) used an assessment factor of 50 applied 252 
to a NOEC of 8 µg/L for Ceriodaphnia dubia reproduction [54] (although the value reported 253 
in Ferrari et al. was actually 9 µg/L).   254 
 255 
CONCLUSIONS 256 
High reliability GVs have been derived for carbamazepine, diclofenac, fluoxetine and 257 
propanolol in fresh waters applying a Burr Type III distribution in SSDs of chronic toxicity 258 
data (NOECs or EC10s). Data were quality assured and had to meet acceptability criteria for 259 
‘chronic’ endpoints.  Sub-chronic biomarker data were excluded from the derivation and only 260 
data for ecologically relevant, population-related effects were included. The derived GVs for 261 
95% species protection were 4.3, 770, 1.6 and 14 µg/L respectively, for the four 262 
pharmaceuticals.  These values significantly higher than the low reliability values derived for 263 
the European Commission, Switzerland or Germany that are based on the application of 264 
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assessment factors to the most sensitive endpoint. They are not exceeded in recent data for 265 
rivers and streams receiving pharmaceutical containing effluents from WWTPs.   266 
  267 
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Table 1.  Key properties of the studied pharmaceuticals 
 
Pharmaceutical Chemical Structure Common 
name 
Log 
Kow 
Solubility, 
mg/L 
pKa Reference 
Carbamazepine 
(anti-convulsant and 
mood stabiliser) 
 
MW =236.3 
Tegretol 2.45 112 13.9 [54] 
Diclofenac       (non-
steroidal anti-
inflammatory) 
 
MW=296.1 
Voltarin 4.51 2,430 4.2 [54] 
Fluoxetine     (anti-
depressant) 
 
MW=309.3 
Prozac, 
Sarafem 
4.05 10,800 9.4 [39, 44, 58] 
Propranolol (beta-
blocker) 
 
MW=259.3 
Inderal 3.12 609 9.5 [54, 59] 
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Table 2.  Chronic data used in carbamazepine guideline derivation 
 
Taxonomic 
group 
Common name Scientific name Life stage Exposure 
duration 
(d) 
Test 
medium 
Test endpoint Toxicity 
estimate 
Toxicity 
value 
(mg/L) 
pH Temp 
(oC) 
Reference 
Blue-green 
algae 
Blue-green 
algae 
Synechococcus 
leopolensis 
- 4 Moderately 
hard water 
Growth 
inhibition 
NOEC 17.5   [54] 
Green algae Green algae Pseudokirchneri
ella subcapitata 
- 4 Freshwater Growth 
inhibition 
NOEC 0.52   [60] 
Green algae Green algae Chlorella 
vulgaris 
- 2 Freshwater Growth 
inhibition 
EC10 13a  22 [61] 
Arthropoda Midge Chironomus 
tepperi 
Embryo 7 Freshwater Larval survival EC10 4.0   [5] 
Diatom  Diatom Cyclotella 
meneghiniana 
- 4 Freshwater Growth 
inhibition 
NOEC 10.0   [54] 
Rotifer Rotifer Brachionus 
calyciflorus 
- 2 Freshwater Reproduction NOEC 0.38   [54] 
Cnidarian Cnidarian Hydra attenuate  3 Freshwater Morphology 
changes 
NOEC 1 7 20 [62] 
Crustacean Water flea Ceriodaphnia 
dubia 
- 7 Freshwater Reproduction NOEC 0.025   [54] 
Crustacean Water flea Daphnia magna  21 Freshwater Reproduction NOEC 0.4   [22, 63] 
Fish Zebrafish Danio rerio Embryo 10  Mortality NOEC 25  23 [54] 
Fish Golden perch Macquaria 
ambigua 
Embryo 7 Freshwater Larval survival EC10 1.1   [5] 
a Estimated from dose-response curve
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Table 3.  Chronic data used to derive diclofenac guideline 
 
Taxonomic 
group 
Common name Scientific name Life stage Exposure 
duration 
(d) 
Test 
medium 
Test endpoint Toxicity 
estimate 
Toxicity 
value 
(mg/L) 
pH Temp 
(oC) 
Reference 
Blue-green 
algae 
Blue-green 
algae 
Synechococcus 
leopolensis 
- 4 Moderately 
hard water 
Growth 
inhibition 
NOEC 10   [54] 
Green algae Green algae Pseudokirchneri
ella subcapitata 
- 4 Moderately 
hard water 
Growth 
inhibition 
NOEC 10   [54] 
Green algae Green algae Desmodesmus 
subspicatus 
- 3 Freshwater Growth 
inhibition 
NOEC 50   [64] 
Arthropod Midge Chironomus 
tepperi 
Embryo 7 Freshwater Larval survival EC10 0.76   [5] 
Angiosperm Duckweed Lemna minor -   Growth 
inhibition 
NOEC 3.5   [5] 
Diatom  Diatom Cyclotella 
meneghiniana 
- 4 Freshwater Growth 
inhibition 
NOEC 10.0   [54] 
Rotifer Rotifer Brachionus 
calyciflorus 
- 2 Freshwater Reproduction NOEC 12.5   [54] 
Crustacean Water flea Ceriodaphnia 
dubia 
- 7 Freshwater Reproduction NOEC 1.0   [54] 
Crustacean Water flea Daphnia magna - 21 Reconstitute
d hard water 
Reproduction NOEC 10 7.8 25 [65] 
Fish Zebrafish Danio rerio Embryo 10 Freshwater Mortality NOEC 4.0  23 [54] 
Fish Golden perch Macquaria 
ambigua 
Embryo 7 Freshwater Larval survival EC10 5.92   [5] 
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Table 4.  Chronic data used to derive the fluoxetine guideline 
 
Taxonomic 
group 
Common name Scientific name Life stage Exposure 
duration 
(d) 
Test 
medium 
Test endpoint Toxicity 
estimate 
Toxicity 
value 
(µg/L) 
pH Temp 
(oC) 
Reference 
Chlorophyta Green alga Pseudokirchneri
ella subcapitata 
- 4 Moderately 
hard water 
Growth 
inhibition 
IC10 31.3 7.3 25 [66] 
Chlorophyta Green alga Pseudokirchneri
ella subcapitata 
- 4 Moderately 
hard water 
Growth 
inhibition 
LOEC 13.6 - 25 [47] 
Chlorophyta Green alga Pseudokirchneri
ella subcapitata 
- 4 Moderately 
hard water 
Growth 
inhibition 
IC50 27 8.1-
8.5 
18-22 [67] 
Chlorophyta Green alga Pseudokirchneri
ella subcapitata 
- 5 Moderately 
hard water 
Growth 
inhibition 
IC50 24 (turb) 
39 (cell 
dens) 
- 25 [48] 
Chlorophyta Green alga Scenedesmus 
acutis 
- 4 Moderately 
hard water 
Growth 
inhibition 
IC10 56 7.3 25 [66] 
Chlorophyta Green alga Scenedesmus 
quadricauta 
- 4 Moderately 
hard water 
Growth 
inhibition 
IC10 98a 7.3 25 [66] 
Chlorophyta Green alga Desmodesmus 
subspicatus 
- 4 Moderately 
hard water 
Growth 
inhibition 
IC10 1.0   [39] 
Chlorophyta Green alga Chlorella 
vulgaris 
- 4 Moderately 
hard water 
Growth 
inhibition 
IC10 2900 7.3 25 [66] 
Chlorophyta Green alga Dunaliella 
tertiolecta 
 4 Moderately 
hard water 
Growth 
inhibition 
IC10 est 24a - 25 [68] 
Arthropod Midge Chironomus 
tepperi 
Embryo 7 Moderately 
hard water 
Larval survival EC10 59   [5] 
Angiosperm Duckweed Lemna minor - ? Moderately 
hard water 
Growth 
inhibition 
EC10 1190   [5] 
Crustacean Amphipod Hyalella azteca - 28 Moderately 
hard water 
Growth 
inhibition 
NOEC 13 7.9 20 [40] 
Crustacean Water flea Ceriodaphnia 
dubia 
- 7 Moderately 
hard water 
Reproduction NOEC 56 - 25 [48] 
Crustacean Water flea Ceriodaphnia 
dubia 
- 7 Moderately 
hard water 
Reproduction NOEC 89  25 [69] 
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       GM 71    
Crustacean Water flea Daphnia magna - 21 Moderately 
hard water 
Reproduction NOEC 174 8.4 25 [43] 
Crustacean Water flea Daphnia magna - 21 Moderately 
hard water 
Reproduction NOEC 8.9 7.9 20 [40] 
Crustacean Water flea Daphnia magna - 21 Moderately 
hard water 
Reproduction NOEC 60   [39] 
       GM 45.3    
Gastropod New Zealand 
mud snail 
Potamopyrgus 
antipodarum 
Embryo 56 Moderately 
hard water 
Survival EC10 0.89 - 16 [41]  
Gastropod New Zealand 
mud snail 
Potamopyrgus 
antipodarum 
Embryo 42 Moderately 
hard water 
Reproduction NEC 5   [40] 
       GM 2.0    
Amphibia African clawed 
frog 
Xenopus laevis Embryo 4 Hard water Malformationb EC10 3000 7.6 23 [42] 
Fish Fathead 
minnow 
Pimephales 
promelas 
Juvenile 7 Moderately 
hard water 
Growthc EC10 9 8.4 25 [43] 
Fish Golden perch Macquaria 
ambigua 
Embryo 7 Freshwater Larval survival EC10 260   [5] 
aEstimated from the published dose response curve; bNot an acceptable endpoint as many factors can lead to malformations; cJuvenile growth must be measured over>21 days
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Table 5.  Chronic data used to derive the propranolol guideline 
 
Taxonomic 
group 
Common name Scientific name Life stage Exposure 
duration 
(d) 
Test 
medium 
Test endpoint Toxicity 
estimate 
Toxicity 
value 
(mg/L) 
pH Temp 
(oC) 
Reference 
Blue-green 
algae 
Blue-green 
algae 
Synechococcus 
leopolensis 
- 4 Moderately 
hard water 
Growth 
inhibition 
NOEC 0.35 7.8 23 [54] 
Green algae Green algae Pseudokirchneri
ella subcapitata 
- 4 Moderately 
hard water 
Growth 
inhibition 
NOEC 5 7.8 23 [54] 
Green algae Green algae Pseudokirchneri
ella subcapitata 
- 3 Deionised 
water 
Growth 
inhibition 
NOEC <0.78 - 24 [70] 
       GM 2.0    
Green algae Green algae Desmodesmus 
subspicatus 
- 3 Moderately 
hard water 
Growth 
inhibition 
EC5 
EC10 
0.18 
0.33 
7.8 23 [52] 
Arthropod Midge Chironomus 
tepperi 
Embryo 7 Moderately 
hard water 
Larval survival EC10 2.06   [5] 
Angiosperm Duckweed Lemna minor - ? Moderately 
hard water 
Growth 
inhibition 
EC10 29.5   [5] 
Diatom  Diatom Cyclotella 
meneghiniana 
- 4 Moderately 
hard water 
Growth 
inhibition 
NOEC 0.094 7.8 23 [54] 
Rotifer Rotifer Brachionus 
calyciflorus 
- 2 Moderately 
hard water 
Reproduction NOEC 0.18 7.8 23 [54] 
Rotifer Rotifer Brachionus 
calyciflorus 
- 2 Deionised 
water 
Reproduction NOEC 1.0 - 24 [70] 
Crustacean Water flea Ceriodaphnia 
dubia 
- 7 Moderately 
hard water 
Reproduction NOEC 0.009 7.8 23 [54] 
Crustacean Water flea Ceriodaphnia 
dubia 
- 7 Reconstitute
d hard water 
Reproduction NOEC 0.125  25 [71] 
       GM 0.033    
Crustacean Water flea Daphnia magna - 9 Hard water Reproduction NOEC 0.055 - 25 [72] 
Fish Rainbow trout Oncorhynchus Juvenile 40 Moderately 
hard fresh 
Growth rate NOEC 8.7
a 7.4 15 [73] 
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mykiss water 
Fish Fathead 
minnow 
Pimephales 
promelas 
Embryo 21 Dechlorinat
ed tap water 
Hatchability NOEC 0.01 7.5 25 [53] 
Fish Golden perch Macquaria 
ambigua 
Embryo 7 Freshwater Larval survival EC10 4.9   [5] 
a Corrected for analytical recovery data
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Table 6.  Derived water quality guidelines for the 4 pharmaceuticals 
 
Pharmaceutical PC99 PC95 PC90 
µg/L 
Carbamazepine <1 4.3 32 
Diclofenac 180 770 1400 
Fluoxetine 0.23 1.6 3.8 
Propranolol 3.5 14 29 
 
 
 
Table 7.  Comparison of derived GVs with other international values  
 
Pharmaceutical EC EQS
a
 Switzerland 
EQS
b
 
German 
EQS
c
 
Other 
values 
This study
d
 
 µg/L  
Carbamazepine - 0.5 0.5 2.1
d,e
 4.3 
Diclofenac 0.1 0.05 0.05 580
d,e
 770 
Fluoxetine 
-
 - - 0.004
f,g
 
0.012
f,h 
0.031
f,i 
0.05
f,j
 
1.6 
Propranolol - 0.16 -  14 
a[74]; b[32]; c[21]; dHC5 (95% species protection)  e[23]; fPNEC values;  
g[50]; h[39]; h[49]; j[2] 
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Figure 1.  SSDs for carbamazepine, diclofenac, fluoxetine and propranolol 
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